2 results match your criteria: "Hannover German Center for Infectious Diseases (DZIF)[Affiliation]"
Reply to 'Chemoprevention of hepatocellular carcinoma in people affected by hepatitis C virus: what changes does the introduction of direct-acting antiviral agents make?'.
Ann Oncol
October 2016
Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover German Center for Infectious Diseases (DZIF), Hannover-Braunschweig, Germany
The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.
Ann Oncol
August 2016
Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover German Center for Infectious Diseases (DZIF), Hannover-Braunschweig, Germany
Hepatitis C infection represents a global health problem affecting ∼200 million chronically infected patients worldwide. Owing to the development of a fibrogenic and inflammatory micromilieu in the liver, hepatitis C virus (HCV)-infected patients are at a high risk of developing fibrosis, cirrhosis and hepatocellular carcinoma (HCC). The advent of direct-acting antiviral agents (DAAs), however, has spurred a revolution in the treatment of HCV patients with sustained viral response (SVR) rates exceeding 90% in real-life settings.
View Article and Find Full Text PDF